IPXL - Impax Laboratories, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Impax Laboratories, Inc.

30831 Huntwood Avenue
Hayward, CA 94544
United States
510-476-2000
http://www.impaxlabs.com

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees1,495

Key Executives

NameTitlePayExercisedAge
Mr. Bryan M. ReasonsSr. VP of Fin. & CFO553.2kN/A50
Mr. Mark A. Schlossberg Esq.Sr. VP, Gen. Counsel & Corp. Sec.572.77kN/A56
Mr. Michael J. NestorPres of Impax Specialty Pharma Division581.85kN/A64
Mr. Douglas S. BoothePres of Impax Generics Division467.2kN/A53
Mr. Paul M. BisaroPres, CEO & DirectorN/AN/A56
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Impax Generics and Impax Specialty Pharma. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance agreements; generic pharmaceutical over-the-counter (OTC) and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance agreements. The Impax Specialty Pharma segment focuses on the development, sale, and distribution through its specialty sales force of proprietary brand pharmaceutical products for the treatment of central nervous system disorders, including migraine, multiple sclerosis, Parkinson’s disease, and post-herpetic neuralgia, as well as other select specialty segments. The company markets and sells its products to drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies in the continental United States and the Commonwealth of Puerto Rico. Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals USA, Inc. to develop, manufacture, and distribute controlled release generic pharmaceutical products. The company was founded in 1993 and is headquartered in Hayward, California.

Corporate Governance

Impax Laboratories, Inc.’s ISS Governance QualityScore as of December 1, 2017 is 4. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 2; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.